drugset / Trial / NCT03822507
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
Phase 3
Completed
404 enrolled
Kyowa Kirin, Inc.
Kyowa Kirin China Pharmaceutical Co., Ltd. · collabKyowa Kirin Korea Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active control in subjects with secondary hyperparathyroidism receiving hemodialysis in China, Korea, Hong Kong and Taiwan.
Timeline
- Start
- 2019-04-09
- Primary completion
- 2021-09-23
- Completion
- 2021-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cinacalcet | Other / unclassified | — | Oral |
| Subject | EVOCALCET | Small molecule | — | Oral |